Japanese biotech company Spiber has raised JPY 5 billion ($43.86 million) via a value securitisation structure arranged by Mitsubishi UFJ Morgan Stanley Securities.
AMSilk and 21st.BIO Forge Alliance to Scale Bioproduced Spider Silk Proteins “From Kilos to Tons”
German Biotech AMSilk GmbH announces a partnership with the Danish bioproduction leader 21st.BIO, to accelerate the production of advanced bioproduced spider silk proteins to meet the growing demand for sustainable material solutions. As part of the collaboration, 21st.BIO has developed precision-fermented microorganisms that can be used to produce silk proteins on an industrial scale. According to 21st.BIO, the new strain ensures the extracellular expression of silk proteins while enabling biomanufacturing at unprecedented productivity levels, supporting higher yield, greater efficiency, and reduced production costs. Gudrun Vogtentanz, CSO at AMSilk, shares: “Through 21st.BIO, we now have access to more efficient production strains, which are a game changer in terms of the efficiency and sustainability of our feedstock. Moving production quantities from kilos to tons brings AMSilk’s technology to the next …